Find a Clinical Trial | American Lung Association

ICoN-1

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)

IMPALA2

To discover whether molgramostim (inhaled GM-CSF) is safe to take and can help to reduce the symptoms of (autoimmune pulmonary alveolar proteinosis ) aPAP.

Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma (MATCH)

The ACRC network is studying whether having regular telehealth appointments with a pharmacist using a study provided tablet or a person’s smart phone or computer will help adolescents and young adults with asthma to gain control of asthma symptoms and improve inhaler effectiveness.

INSIGNIA PH-COPD

Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease.

KEYLYNK-012

This study is looking at how pembrolizumab with chemotherapy and radiation followed by pembrolizumab plus olaparib (or placebo for olaparib) works compared to chemotherapy and radiation followed by durvalumab.

KEYLYNK-013

This clinical trial is trying to find out if a combination of study drugs can help stop or slow down this type of cancer.

LUNG STAAR

The purpose of this research is to offer patients with centrally located early-stage non-small cell lung cancer (NSCLC) who are NOT candidates for surgery the opportunity to receive stereotactic body radiation therapy (SBRT).

Miranda

Tozorakimab is hypothesized to have a beneficial effect in patients with COPD by reducing the frequency and severity of COPD exacerbations and improving COPD symptoms and quality of life.

MIST

This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 versus placebo on top of standard of care in participants with PPF over 52 weeks. Up to 300 eligible participants will be randomized to 1 of 3 treatment arms: AP01 high dose, AP01 low dose, or placebo.

Optimizing self-management COPD treatment through the American Lung Association Helpline

The current study will test the feasibility of using an engineering-inspired study design to identify effective COPD self-management treatment components.

Next